DK3864053T3 - Behandling af rms ved at skifte terapi - Google Patents

Behandling af rms ved at skifte terapi Download PDF

Info

Publication number
DK3864053T3
DK3864053T3 DK20785440.7T DK20785440T DK3864053T3 DK 3864053 T3 DK3864053 T3 DK 3864053T3 DK 20785440 T DK20785440 T DK 20785440T DK 3864053 T3 DK3864053 T3 DK 3864053T3
Authority
DK
Denmark
Prior art keywords
rms
treatment
changing therapy
therapy
changing
Prior art date
Application number
DK20785440.7T
Other languages
Danish (da)
English (en)
Inventor
Krishnan Ramanathan
Dieter Adrian Haering
Morten Bagger
Martin Merschhemke
Marina Ziehn
Ratnakar Pingili
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3864053(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3864053T3 publication Critical patent/DK3864053T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK20785440.7T 2019-09-11 2020-09-10 Behandling af rms ved at skifte terapi DK3864053T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19196789 2019-09-11
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Publications (1)

Publication Number Publication Date
DK3864053T3 true DK3864053T3 (da) 2023-09-11

Family

ID=72709332

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20785440.7T DK3864053T3 (da) 2019-09-11 2020-09-10 Behandling af rms ved at skifte terapi

Country Status (15)

Country Link
US (1) US20220298253A1 (https=)
EP (2) EP4230655A3 (https=)
JP (2) JP7794735B2 (https=)
KR (1) KR20220062025A (https=)
CN (3) CN118436777A (https=)
AU (1) AU2020344154A1 (https=)
CA (1) CA3150947A1 (https=)
DK (1) DK3864053T3 (https=)
ES (1) ES2957112T3 (https=)
FI (1) FI3864053T3 (https=)
IL (1) IL290619A (https=)
LT (1) LT3864053T (https=)
MX (1) MX2022003010A (https=)
SI (1) SI3864053T1 (https=)
WO (1) WO2021048280A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120053638A (zh) 2016-08-15 2025-05-30 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法
MX2022003030A (es) * 2019-09-11 2022-04-07 Novartis Ag Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab.
US20230151106A1 (en) * 2020-04-09 2023-05-18 Novartis Ag OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG
US20240228647A1 (en) * 2021-04-14 2024-07-11 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
EA201692180A1 (ru) * 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN120053638A (zh) 2016-08-15 2025-05-30 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法

Also Published As

Publication number Publication date
ES2957112T3 (es) 2024-01-11
IL290619A (en) 2022-04-01
EP3864053B1 (en) 2023-07-05
CN114401742B (zh) 2024-05-24
CN118436777A (zh) 2024-08-06
CN118403156A (zh) 2024-07-30
CA3150947A1 (en) 2021-03-18
CN114401742A (zh) 2022-04-26
SI3864053T1 (sl) 2023-12-29
FI3864053T3 (fi) 2023-09-13
MX2022003010A (es) 2022-06-02
KR20220062025A (ko) 2022-05-13
EP4230655A3 (en) 2023-11-01
JP7794735B2 (ja) 2026-01-06
JP2026016387A (ja) 2026-02-03
EP4230655A2 (en) 2023-08-23
EP3864053A1 (en) 2021-08-18
AU2020344154A1 (en) 2022-04-07
US20220298253A1 (en) 2022-09-22
WO2021048280A1 (en) 2021-03-18
JP2022548575A (ja) 2022-11-21
LT3864053T (lt) 2023-09-11

Similar Documents

Publication Publication Date Title
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
DK3864053T3 (da) Behandling af rms ved at skifte terapi
DK4010329T3 (da) Deutererede forbindelser til anvendelse ved behandling af cancer
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
DK4331584T3 (da) Terapeutiske anvendelser af deutererede derivater af lanifibranor
DK3658141T3 (da) Behandling af patologiske tilstande ved direkte og indirekte målretning af Sirpalpha-CD47-interaktion
EP4031120A4 (en) Treatment of syngap1 encephalopathy
IL287904A (en) Combination treatment of arthritic disease
EP3975919C0 (en) SWEEPABLE HEALING COMPONENTS
IL282311A (en) Use of reboxetine to treat narcolepsy
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
DK3886799T3 (da) Sammensætninger til behandlingen af hårtab
DK3565592T5 (da) Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
DK3899113T3 (da) Fremgangsmåde til behandling af lyocellfibre
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
DK3463328T3 (da) Seladelpar til behandling af primær biliær cholangitis
DK3390448T3 (da) Intravesikal terapi af blærekræft
DK3743064T3 (da) Behandling af proteinuri
EP4073003A4 (en) Plasma water treatment
DK3833378T3 (da) Behandling af vorter
DK3749336T3 (da) Sårbehandlingsgel opnåelig ved at kombinere blodpladerigt plasma med autolog-afledt thrombin
EP3836935A4 (en) TREATMENT OF B LYMPHOCYTE MALIGNITIES
IL288237A (en) Combination therapy
IL289338A (en) Therapeutic interactions of leucomethylthioninium
DK3532072T3 (da) Behandling af glaukom